Name: | doxacurium chloride |
---|---|
Name (isomeric): | DB01135 |
Drug Type: | small molecule |
Brand: | Nuromax |
Category: | Neuromuscular Nondepolarizing Agents |
CAS number: | 106819-53-8 |
Indication: | Used to provide skeletal muscle relaxation as an adjunct to general anesthesia, for endotracheal intubation or to facilitate mechanical ventilation. |
---|---|
Pharmacology: |
Doxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant. The neuromuscular block produced by doxacurium chloride may be antagonized by anticholinesterase agents. As with other nondepolarizing neuromuscular blocking agents, the more profound the neuromuscular block at reversal, the longer the time and the greater the dose of a...
show more » |
Mechanism of Action: | Doxacurium chloride binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission (non-depolarizing). This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine. |
Protein binding: | Approximately 30%. |
Biotransformation: | In vivo data from humans suggest that doxacurium chloride is not metabolized and that the major elimination pathway is excretion of unchanged drug in urine and bile. |
Route of elimination: | In vivo data from humans suggest that NUROMAX is not metabolized and that the major elimination pathway is excretion of unchanged drug in urine and bile. |
Half Life: | 99 minutes in normal healthy adults. |
Clearance: | 2.66 mL/min/kg [Healthy Young Adult Patients] 1.23 mL/min/kg [Kidney Transplant Patients] 2.3 mL/min/kg [Liver Transplant Patients] 1.75 +/- 0.16 mL/min/kg [Elderly patients (70-83 yrs)] 2.54 +/- 0.24 mL/min/kg [younger patients (19-39 yrs)] |
Toxicity: | Overdosage with neuromuscular blocking agents may result in neuromuscular block beyond the time needed for surgery and anesthesia. |
Affected organisms: | Humans and other mammals |
Drug interaction: |
|
---|